247 related articles for article (PubMed ID: 30115676)
1. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
[TBL] [Abstract][Full Text] [Related]
2. Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
Hiremath SB; Muraleedharan A; Kumar S; Nagesh C; Kesavadas C; Abraham M; Kapilamoorthy TR; Thomas B
AJNR Am J Neuroradiol; 2017 Apr; 38(4):685-690. PubMed ID: 28209583
[TBL] [Abstract][Full Text] [Related]
3. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
[TBL] [Abstract][Full Text] [Related]
4. Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.
Lu SS; Kim SJ; Kim HS; Choi CG; Lim YM; Kim EJ; Kim DY; Cho SH
AJNR Am J Neuroradiol; 2014 Feb; 35(2):270-7. PubMed ID: 23928144
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions.
Cha S; Pierce S; Knopp EA; Johnson G; Yang C; Ton A; Litt AW; Zagzag D
AJNR Am J Neuroradiol; 2001; 22(6):1109-16. PubMed ID: 11415906
[TBL] [Abstract][Full Text] [Related]
6. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
Saini J; Chatterjee S; Thomas B; Kesavadas C
Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
[TBL] [Abstract][Full Text] [Related]
7. Distinguishing tumefactive demyelinating lesions from glioma or central nervous system lymphoma: added value of unenhanced CT compared with conventional contrast-enhanced MR imaging.
Kim DS; Na DG; Kim KH; Kim JH; Kim E; Yun BL; Chang KH
Radiology; 2009 May; 251(2):467-75. PubMed ID: 19261924
[TBL] [Abstract][Full Text] [Related]
8. Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.
Barbosa BC; Marchiori E; Leal Leidersnaider C; Brandao L; Castillo M
Neuroradiol J; 2019 Apr; 32(2):103-107. PubMed ID: 30667319
[TBL] [Abstract][Full Text] [Related]
9. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy.
Cianfoni A; Niku S; Imbesi SG
AJNR Am J Neuroradiol; 2007 Feb; 28(2):272-7. PubMed ID: 17296993
[TBL] [Abstract][Full Text] [Related]
10. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
[TBL] [Abstract][Full Text] [Related]
11. Value of 18F-FET PET in Patients With Suspected Tumefactive Demyelinating Disease-Preliminary Experience From a Retrospective Analysis.
Barbagallo M; Albatly AA; Schreiner S; Hayward-Könnecke HK; Buck A; Kollias SS; Huellner MW
Clin Nucl Med; 2018 Nov; 43(11):e385-e391. PubMed ID: 30153143
[TBL] [Abstract][Full Text] [Related]
12. Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.
Malhotra HS; Jain KK; Agarwal A; Singh MK; Yadav SK; Husain M; Krishnani N; Gupta RK
Mult Scler; 2009 Feb; 15(2):193-203. PubMed ID: 19181773
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of tumefactive demyelinating lesions and differential features for multiple sclerosis in etiology.
Saridas F; Mesut G; Ceylan CY; Ozpar R; Ozsen M; Koc ER; Tolunay S; Hakyemez B; Turan OF
Mult Scler Relat Disord; 2024 May; 85():105537. PubMed ID: 38460252
[TBL] [Abstract][Full Text] [Related]
14. Imaging of Fulminant Demyelinating Disorders of the Central Nervous System.
Razek AAKA; Elsebaie NA
J Comput Assist Tomogr; 2020; 44(2):248-254. PubMed ID: 32195804
[TBL] [Abstract][Full Text] [Related]
15. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
[TBL] [Abstract][Full Text] [Related]
16. Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study.
Altintas A; Petek B; Isik N; Terzi M; Bolukbasi F; Tavsanli M; Saip S; Boz C; Aydin T; Arici-Duz O; Ozer F; Siva A
Mult Scler; 2012 Oct; 18(10):1448-53. PubMed ID: 22419670
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of tumefactive demyelinating lesions from high-grade gliomas with the use of diffusion tensor imaging.
Toh CH; Wei KC; Ng SH; Wan YL; Castillo M; Lin CP
AJNR Am J Neuroradiol; 2012 May; 33(5):846-51. PubMed ID: 22173757
[TBL] [Abstract][Full Text] [Related]
18. Tumefactive demyelinating lesion: experience with two unusual patients.
Sinha MK; Garg RK; Bhatt ML; Chandra A
J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
[TBL] [Abstract][Full Text] [Related]
19. Mass lesions in the brain: tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center.
Kilic AK; Kurne AT; Oguz KK; Soylemezoglu F; Karabudak R
Turk Neurosurg; 2013; 23(6):728-35. PubMed ID: 24310455
[TBL] [Abstract][Full Text] [Related]
20. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
